OUR COMPANY
InBrain Pharma is a biotech specialized in brain infusion of drugs for neurological disorder management. InBrain Pharma's approach is unique and groundbreaking in the treatment of advanced Parkinson's disease, offering continuous dopaminergic stimulation in the brain of patients at the stage of severe and refractory motor complications related with L-dopa oral treatment. This pharmacological modulation of dopamine neurotransmission is achieved by continuous, titrated intracerebroventricular (i.c.v.) administration of dopamine. This new therapeutic modality opens the era of precision medicine for neurodegenerative diseases management.
Therapeutic concept
Pharmacological neuromodulation
The brain is a special organ which requires a specific care-management. Indeed, oral treatments are problematics and cause many side effects due to their diffusion to the whole body, whereas only the brain is targeted.
Moreover, the efficacy of oral treatments is often limited by the dose and the short administration time. Also, many therapeutic solutions do not pass the digestive barrier and the blood-brain barrier.
On the other hand, controlled administration in the central nervous system allows a precise, continuous and targeted administration directly into the brain, increasing the efficacy and safety of treatments, particularly for severe diseases of the central nervous system.
InBrain Pharma is developing this concept of pharmacological neuromodulation.
Neurodegenerative diseases
Neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS)... represent a major challenge for our society. They affect millions of patients and inexorably progress inexorably towards disability and death without treatmentcapable of slow this progression and bring catastrophic socio-economic consequences.
Parkinson's disease is linked to the degeneration of dopaminergic neurons in the black substance. It is the second most common neurodegenerative disease with 6,500,000 patients worldwide and 1-2% of the population over 65 years of age affected. The disease is manifested by akinesia, tremors, rigidity, postural instability and many other non-motor signs (depression, anxiety, pain, intellectual and behavioural disorders, etc.). InBrain Pharma targetting the advanced stage of Parkinson's Disease.
Technology
A-Dopamine : Parkinson's disease treatment
A-Dopamine is a Device Aided Therapy consisting in a continuously administration of the missing dopamine into the brain of patients with Parkinson's Disease, particularly at the advanced stage of complications related to oral dopamine treatment (L-dopa).
At this stage, therapeutic alternatives are often proposed. These alternatives are invasives, not very ergonomics friendly or doesn't control gait and speech disorders as well as emotional disability. A-Dopamine therapy will significantly improve motor disability and quality of life without altering walking, speech and emotional disability. This approach of continuous compensation of missing dopamine is made possible thanks to our new technology of natural dopamine preparation limiting the dopamine oxidation. This therapeutic innovation will be to parkinsonians what the insulin pump is to diabetics.
Strategic partnerships:
Academic and private :
InBrain Pharma has partnerships with :
- The labolatory UMR-S 1172 specialized in the treatment of degenerative and vascular cognitive disorders of the University of Lille, CHRU of Lille, INSERM
- The labolatory EA7365 specialized in the administration of injectable drugs of the University of Lille.
- Tricumed : German manufacturer of Siromedes pumps.
- Flowonix : American manufacturer of Prometra pumps.
TEAM
The team has already proven itself individually and collectively and has been carrying this project for 12 years.
Véronique Foutel,
PharmD
CEO
- With 30+ years of experience dedicated to Life Science innovation, encompassing 16 years within the Pharma Division of F. Hoffmann La Roche AG.
- She Involved in 120+ drug asset assessments (all LC stages/all TAs) & 30+ Due Diligence WW.
- Ex-Global Head of the Roche Pharma Strategic Pricing for new products
- Strategic advisor to Pharma / biotech management Teams since 2012
- Holding a Pharmaceutical sciences doctorate from Paris Cité University, former Paris Hospital Residency
Matthieu Fisichella,
PhD
CSO
Co-founder
- Doctor-Engineer in Biology
- Challenge+, HEC
- Former CEO of InBrainPharma
- Project manager in life sciences at SATT Nord
- Scientific and partnership manager at Primadiag
- 10 projects evaluated and structured, 55 technologies detected, +€2m of budget obtained and managed, 2 projects transferred
David Devos,
MD, PhD
Preclinical and clinical scientific advisor
Co-founder
- Director of Neuroscience research team DVCD INSERM UMRS-U1172
- Neurologist, Professor of Medical Pharmacology, Faculty of Medicine & Neurologist University Hospital
- Executive board member of the Parkinson network Ns-Park
366+publications including 250+ articles, H-Index > 60, 31 clinical studies including 14 multicenter studies and 14 as coordinator (10 in progress), 5 academic patents filed
Caroline Moreau, MD,PhD
Clinical scientific advisor
Co-founder
- Professorof Neurology at Lille University hospital
- Assistant Secretary of the French Society of Neurology French representative at the European Academy of Neurology
- 130+articles, 34 clinical studies including 14 multicenter studies and 5 as coordinator, 5 patents and 2 industrial transfers
Marine Rebier
Administrative and Legal Officer
- With its experience in the international groups Promod and Damartex, and in the pharmaceutical group Macopharma,
- She deals in particular with national and international contracts, corporate law and issues related to public health law.
Simon Baigné, PharmD
Regulatory Affairs and Clinical Operations Officer
- With a master's degree in Pharmacy and a previous experience as regulatory affairs manager
- He joined us to develop our new technologies and ensure regulatory compliance.
Ours investors
Fondation of the Univeristy of Lille
Created at the end of 2014 with an initial endowment of €15 million, the Fondation of the University of Lille combines the flexibility and agility inherent with its status as a legal entity under private law with a strong vocation to support excellence in training and research, to develop pedagogical, technological and scientific innovation and to contribute to the influence and attractiveness of the University of Lille. It is thus the agency of means at the service of the University of Lille's ambition for excellence. The Foundation is also perfectly integrated into its ecosystem, since the President of the European Metropolis of Lille, the President of the MEDEF Hauts-de-France and the General Director of the Lille University Hospital are members of its Board of Directors.
FINOVAM Gestion
FINOVAM GESTION manages €50 million through two funds for a portfolio of 28 companies in the "Hauts-de-France" and "Grand-Est" regions. FIRA NORTD-EST aims to enable the emergence of companies with high growth potential in cutting-edge sectors in the North-East quarter of France. FIRA NORD-ESTT invests from €300 K to €2.5 M per project.
The fund has the support of the Hauts-de-France and Grand-Est Regional Councils alongside BNP Paribas, Crédit Agricole Nord de France, Crédit Agricole Brie Picardie, Crédit Agricole de Lorraine, Caisse d'Epargne Hauts-de-France, Caisse d'Epargne Lorraine Champagne-Ardenne, and Adeo, Lesaffre and Tereos Groups, and privete investors.
Nord France Amorçage
created in February 2013, Nord France Amorçage is today a 30 million euro fund. It is fully owned by the Region, which mobilises FEDER funds to the amount of €21.5 million to provide equity capital to innovative regional SMEs.
This fund is part of the Research and Innovation Strategy and aims to provide better support and funding for innovation. It is managed by the Siparex Group, an independent specialist in private equity for SMEs.
